OncoMatch/Clinical Trials/NCT04322890
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Is NCT04322890 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for non small cell lung cancer.
Treatment: Osimertinib · Alectinib 150 MG · Crizotinib 250 MG · Savolitinib, Crizotinib. · Chemotherapy — The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR oncogenic mutation
Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
Required: ALK oncogenic mutation
Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
Required: ROS1 oncogenic mutation
Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
Required: MET oncogenic mutation
Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Adequate bone marrow hematopoiesis
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate bone marrow hematopoiesis and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04322890 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require EGFR?
Yes, EGFR oncogenic mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK oncogenic mutation is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 oncogenic mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify